Where is GHK-Cu typically injected in research?

When subcutaneous injection is used in animal or research models, the standard sites are the same as for other research peptides: lateral abdominal fat, the dorsal subcutaneous space, or the thigh. Site rotation reduces local irritation. Many cosmetic-research studies use topical or iontophoretic routes instead, since GHK-Cu's copper complex penetrates the stratum corneum directly.

GHK-Cu is an endogenous human tripeptide - your own plasma already contains it (about 200 ng/mL at age 20, declining to ~80 ng/mL by age 60). Published research has not identified serious systemic toxicity at the research doses described, and the copper(II) binding constant (log K ≈ 16.44) means it transports copper without triggering Fenton-chemistry oxidative damage. It is, however, a research compound and not a medicine; New-U supplies it for in-vitro and preclinical laboratory research only.

Shop by goal

Metabolic Research

GH-Axis Research

Muscle & IGF Research

Tissue and Cellular Models

Regenerative Research

Cellular Senescence Research

Cognitive Research

Multi-Compound Blends

Popular compounds

Research resources

GHK-Cu Dosage Guide: How Much, How Often, Topical vs Injection

Q: How much GHK-Cu is used per day in research?

The published research literature describes topical formulations at roughly 1–10 μg per application and subcutaneous injection studies in the 50–200 μg range, typically 2–3 times weekly. Plasma half-life of the free tripeptide is under 30 minutes and ~95% is cleared after dermal injection. This is descriptive research context, not a dosing instruction; GHK-Cu is supplied for research use only.

Q: How often is GHK-Cu injected in research protocols?

Subcutaneous injection studies typically describe 2–3 sessions per week rather than daily dosing, because the active gene-expression and angiogenic signalling occurs at picomolar concentrations and the systemic effects persist beyond the short plasma half-life. Topical research formulations are usually applied once or twice daily.

Q: How do you reconstitute GHK-Cu?

Use bacteriostatic water for injection. Add water slowly down the side of the vial; do not shake vigorously, swirl gently until the powder dissolves. The reconstituted solution has a characteristic blue tint from the copper complex. Store at 1–6 °C, protect from light, and use within the validated stability window for the batch. Unreconstituted lyophilised powder stays in a −20 °C freezer.

Q: Is GHK-Cu FDA approved?

No. GHK-Cu is not an FDA-approved drug. Copper tripeptide-1 is permitted as a cosmetic ingredient, and GHK-Cu is studied extensively in academic regenerative-medicine, wound-healing and dermatology research. New-U Research Compounds supplies it as a research-grade lyophilised powder strictly for laboratory research - not for human consumption or therapeutic use.

Q: Does GHK-Cu help with acne and acne scars?

In research and cosmetic-chemistry contexts, yes. GHK-Cu suppresses NF-κB-driven inflammation, accelerates wound-bed remodelling, and stimulates dermal collagen and glycosaminoglycan synthesis at picomolar concentrations. These mechanisms underpin its use in studies of post-inflammatory acne marks and atrophic scar remodelling. Effects are reported with sustained topical exposure rather than single-dose application.

Q: How long does GHK-Cu take to work?

In cosmetic-chemistry studies, visible skin endpoints (texture, fine-line depth, photoaging markers) are typically measured after 4–12 weeks of sustained topical exposure. Gene-expression and fibroblast-activation effects are documented within hours in vitro, and wound-healing studies in animal models show measurable remodelling within days. Timelines depend on route, concentration, frequency, and the specific endpoint.

GHK-Cu is one of the most-searched research peptides on the internet right now, and the most common question we see is the simplest one: how much . This page is a research-grade reference to what the published literature actually says - topical concentrations, subcutaneous μg ranges, frequency, reconstitution math, safety profile and onset timelines.

Everything below is descriptive research context drawn from peer-reviewed sources. GHK-Cu is supplied by New-U Research Compounds as a lyophilised powder for in-vitro and preclinical research use only . Nothing on this page is medical advice or a human-use dosing instruction. For mechanism and study landscape, start with our GHK-Cu research guide.

30-second summary: Topical research formulations: ~1–10 μg per application, 1–2× daily. Subcutaneous research studies: ~50–200 μg per session, 2–3× weekly. Reconstitute with bacteriostatic water (blue tint = copper complex working). Store cold, protect from light. Endogenous tripeptide; not FDA-approved as a drug.

How Much GHK-Cu Is Used Per Day in Research?

The published research literature converges on two dose ranges, depending on route:

Route Typical research range Frequency Notes Topical (cosmetic-chemistry studies) 1–10 μg per application, in a 0.05–2% formulation Once or twice daily Only copper-complexed forms (GHK-Cu and (GHK)₂-Cu) cross the stratum corneum in membrane-model studies. Unliganded GHK shows weaker topical activity. Subcutaneous injection (animal/preclinical studies) 50–200 μg per session 2–3 times per week Plasma half-life of the free tripeptide is under 30 minutes; ~95% cleared after dermal injection. Effects persist through downstream gene expression, not plasma residence. Iontophoresis / microneedle Equivalent to topical, but with deeper dermal delivery Per study protocol Used when researchers want topical-style local action with enhanced penetration.

The numbers are smaller than people expect because GHK-Cu is active at picomolar to nanomolar concentrations in vitro . It's a signalling tripeptide, not a structural ingredient - it tells fibroblasts what to do, then the cellular response carries the work.

How Often Is GHK-Cu Injected in Research Protocols?

Daily injection is uncommon in the GHK-Cu literature. Most subcutaneous protocols describe 2–3 sessions per week , for two reasons:

The active signal is gene-expression modulation. Once the cell receives the cue, the downstream transcriptional response continues for many hours after plasma levels drop.

The free tripeptide is cleared within minutes. Daily redosing does not meaningfully accumulate; spaced dosing matches the biology better.

Topical formulations are different - they are reapplied once or twice daily because the goal is sustained local exposure of skin fibroblasts.

Where Is GHK-Cu Injected in Research?

When subcutaneous injection is used in research models, the standard sites are the same as for other research peptides: lateral abdominal fat (away from the umbilicus), the dorsal subcutaneous space, or the lateral thigh. Site rotation reduces local copper-related discoloration and irritation. Many dermatology and cosmetic-chemistry studies skip injection entirely and use topical or iontophoretic delivery, since the copper complex penetrates the stratum corneum directly.

How Do You Reconstitute GHK-Cu?

GHK-Cu ships as a lyophilised (freeze-dried) powder with a faint blue tint from the copper. Reconstitution is straightforward:

Use bacteriostatic water for injection. Sterile water works but bacteriostatic water (with 0.9% benzyl alcohol) is preferred for multi-day vials.

Add the water slowly down the side of the vial. Do not shoot it directly onto the powder, and do not shake - peptides denature under mechanical stress.

Swirl gently until fully dissolved. The solution will turn a clear, characteristic blue. That blue is the copper(II)–tripeptide complex; if you do not see blue, the copper complex has been disrupted.

Store at 1–6 °C , protect from light, and use within the validated stability window for your batch and concentration. Unreconstituted powder stays in a −20 °C freezer until use.

For the volume math (how much water to add to hit a target μg per IU on your syringe), use our reconstitution calculator. The volume equation is simply volume = mg / target concentration - it is a math utility, not a dose-calculator that suggests what to inject.

Is GHK-Cu Safe?

GHK-Cu is an endogenous human tripeptide. Your own plasma contains it: about 200 ng/mL at age 20, declining to around 80 ng/mL by age 60. That endogeneity is the foundation of its safety profile - your body has been clearing GHK and GHK-Cu on its own for decades.

In published research, no serious systemic toxicity has been reported at the dose ranges described above. The copper(II) binding constant (log K ≈ 16.44 at physiological pH) is high enough that GHK-Cu transports copper into cells without triggering the Fenton-chemistry oxidative damage that free copper ions can cause. That is the entire reason copper has to be chaperoned by a peptide carrier in this kind of research.

That said: GHK-Cu is a research compound, not a medicine. New-U makes no human-use claims, supplies material for laboratory research only, and the safety summary above is descriptive research context - not a clearance for self-administration.

Is GHK-Cu FDA Approved?

No. GHK-Cu is not an FDA-approved drug. Two distinct facts get confused here:

Cosmetic ingredient: Copper tripeptide-1 (the cosmetic-chemistry name for GHK-Cu) is a permitted ingredient in topical cosmetic products. That is not the same as drug approval.

Research compound: GHK-Cu is studied extensively in academic regenerative-medicine, wound-healing, dermatology and hair-biology research, but it has not gone through an FDA new-drug approval process for any indication.

For a longer treatment of how research peptides relate to the FDA's compounding framework, see peptides and FDA approval and are peptides legal.

Does GHK-Cu Cause Cancer?

Published research on GHK-Cu has not identified a carcinogenic signal. The mechanism people sometimes worry about - that anything which stimulates cell growth must also accelerate tumour growth - does not hold here. GHK-Cu's gene-expression effects are regenerative (collagen synthesis, angiogenesis, wound-bed remodelling), and Hong et al. (2012, BioMed Research International ) actually showed that the related GHK tripeptide can reset gene expression in metastatic colon-cancer cells toward a more normal, less metastatic profile.

This is not a clearance for any specific clinical or self-use scenario. It is a summary of what the published preclinical literature reports. Any decision to use GHK-Cu in a given research model should be guided by your institution's research-ethics framework and the current peer-reviewed literature.

Does GHK-Cu Help with Acne and Acne Scars?

In research and cosmetic-chemistry contexts, yes - the mechanism is plausible and the literature supports it. GHK-Cu:

Suppresses NF-κB -driven inflammation (the master switch behind most inflammatory acne)

Accelerates wound-bed remodelling and re-epithelialisation

Stimulates dermal collagen and glycosaminoglycan synthesis at picomolar concentrations

Promotes angiogenesis in damaged dermis (improving the blood supply that atrophic scars sit on top of)

Together those mechanisms support its use in studies of post-inflammatory acne marks (PIE / PIH) and atrophic acne-scar remodelling. Effects are reported with sustained topical exposure - usually weeks, not days. Companion peptides like Matrixyl and Argireline are sometimes stacked for multi-pathway skincare research.

How Long Does GHK-Cu Take to Work?

Time-to-effect depends on what endpoint you are measuring:

Endpoint Reported timeline Fibroblast gene-expression changes in vitro Hours Wound-bed remodelling in animal models Days Hair follicle metrics (anagen prolongation, follicle size) 2–6 weeks Visible skin endpoints (texture, fine-line depth, photoaging markers) in cosmetic studies 4–12 weeks of sustained topical exposure Sustained dermal density / elasticity changes 8–12 weeks+

For one writer's field note on dermal density changes observed in the field (specifically: a tattoo artist noticing skin density mid-session), see GHK-Cu & skin thickness: a field note from the tattoo chair.

Where Can Researchers Buy GHK-Cu?

New-U Research Compounds supplies GHK-Cu as a lyophilised, copper-complexed powder in 10-vial research packs at 50 mg or 100 mg per vial. Every batch is independently verified at >99% HPLC purity by Janoshik Analytics and Freedom Diagnostics, with the batch-linked Certificate of Analysis published online. Direct-from-source pricing, discreet tracked shipping (6–14 days worldwide), free shipping over $350, card and cryptocurrency accepted.

From the Lab - Peptides on LinkedIn & Facebook

Lab-Verified GHK-Cu

10-vial research packs · >99% HPLC purity · Janoshik & Freedom Diagnostics verified · Direct from source.

Continue Reading

GHK-Cu copper peptide research guide - mechanism, gene-expression, the full study landscape

GHK-Cu & skin thickness - a field note on dermal density

Peptides for skin & collagen - the broader skin-peptide landscape

How to reconstitute peptides - bacteriostatic water, swirl don't shake, the math

Peptides and FDA approval - what "research compound" actually means

GHK-Cu is a research compound. New-U Research Compounds supplies it for in-vitro and preclinical laboratory research only. Nothing on this page is medical advice, a dosing instruction, or a recommendation for human use. Not for human use.

Research-grade · >99% HPLC purity · COA per lot

Buy GHK-Cu from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. Research use only - all claims made on this site are for testing and research use only.

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research